In January 2022, CLINUVEL announced that it had completed enrolment in its world-first study of afamelanotide as a treatment for arterial...

Ischaemic strokes cause irreversible damage. They begin suddenly and the damage escalates if the stroke is not treated quickly.

CLINUVEL has today announced that its drug afamelanotide was well tolerated by the first three arterial ischaemic stroke (AIS) patients enrolled in a world first clinical trial (CUV801). Watch our new video explaining the pathology and treatment of stroke.

Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...

Reduced staff over the weekends is the norm for many retail shops, but what about in healthcare? A number of reviews have...

Those of us working from offices, or our own homes, aren’t expecting danger pay.  However, what about those who have jobs that heighten the risk of getting skin...

Most of us have been spun a myth that eating our crusts will make our hair shiny, and that we should...

Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...

In a webcast addressed to shareholders, CLINUVEL’s Managing Director, Dr Philippe Wolgen, covers CLINUVEL’s market position, financial management and the Group’s unfolding growth and expansion strategy.

CLINUVEL’s Chief Financial Officer, Darren Keamy, and Director of Global Operations, Lachlan Hay, discuss the financial results for the half year ended 31 December 2021, the Company’s multi-pronged growth and expansion strategy and the activities of the Pharmaceuticals and Healthcare Solutions Divisions.

Following the release of CLINUVEL’s latest Appendix 4C, CLINUVEL’s Head of Investor Relations, Malcolm Bull, and CFO, Darren Keamy, discuss operations underpinning the result.

On November 10th 2021 CLINUVEL PHARMACEUTICALS live streamed its 2021 Annual General Meeting